Tests early catheter ablation for irregular heartbeat in people with heart failure
Tests early catheter ablation for atrial fibrillation in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure
Key facts
- Where
- Aalborg, Aarhus, Copenhagen, Hellerup, Odense, and Roskilde, DenmarkSee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06560047, who can take part
Where in Denmark
- Aalborg University Hospital, Department of CardiologyAalborg, DenmarkTaking people
- Aarhus University HospitalAarhus, DenmarkNot yet recruiting
- Department of Cardiology, RigshospitaletCopenhagen, DenmarkTaking people
- Department of Cardiology, Herlev-Gentofte University HospitalHellerup, DenmarkTaking people
- Department of Cardiology, Odense University HospitalOdense, DenmarkNot yet recruiting
- Department of Cardiology, Zealand University HospitalRoskilde, DenmarkNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aalborg University Hospital
- Trial code
- NCT06560047
- Record updated
- 30 August 2024
- Original description
The DanAblate-HF trial will investigate whether early catheter ablation treatment for atrial fibrillation in patients with heart failure is superior to standard treatment.Read full original descriptionShow less
Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure - The DanAblate-HF Trial
The DanAblate-HF trial will investigate whether early catheter ablation treatment for atrial fibrillation in patients with heart failure is superior to standard treatment.
Inclusion: HF patients with AF within the past 12 months; HF is defined as all of the below (all must apply); Clinically assessed Heart Failure with Reduced Ejection Fraction (HFrEF); An indication for initiation or ongoing guideline directed medical therapy for HFrEF, according to current Heart Failure guidelines; LVEF < 50% at any point during the past 12 months; AF is defined as one or more of the following:; Symptomatic AF, documented by ECG, Holter of CIED; Asymptomatic AF with one or more of the following:; Clinical indication for rhythm or rate control (documented by ECG, telemetry, Holter, CIED); ≥2 ECG detected AF episodes within 3 months (on separate dates); Holter detected AF with a continuous duration of more than 6 hours; CIED detected AF with continuous duration >24 hours; 18 years ≤ Age <80 years; Optimal medical therapy for HFrEF or planned/current uptitration in guideline directed medical therapy for HFrEF; Treatment with anticoagulation for stroke prevention, initiated according to guidelines for treatment of AF.
Exclusion: Contraindications or unacceptable side effects to rate limiting drugs AND amiodarone; Previous AF ablation/surgery; Planned cardiothoracic surgery; Contraindications for anticoagulation therapy or catheter ablation; Patient unwilling to try medical therapy for AF; Reversible causes of AF (including, but not limited to, infection within 14 days, untreated thyroid disease, surgery); Severe valvular disease; Acute myocardial infarction, cardiothoracic surgery or stroke within the past 3 months; Listed for heart transplant; Severe kidney disease (CKD≥5); Life-expectancy < 1 year; BMI > 40; LA size (indexed for BSA) > 60 ml/m2 (volume) on echo within the last year; Documented persistent/permanent AF > 1 year; Pregnancy; Patient unwilling/unable to give informed consent for study participation.